Brief Enhanced Anxiety Sensitivity Treatment (Group BEAST) for Anxiety

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Ohio University, Athens, OH
Anxiety+3 More
Brief Enhanced Anxiety Sensitivity Treatment (Group BEAST) - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

One-third of the U.S. population experience anxiety disorders in their lifetime and only 25% of them seek treatment, reporting logistics and cost of treatment among the primary barriers. A potential way to prevent and treat multiple anxiety disorders is to target the risk factors that contribute to their etiology. One such well-researched risk factor is anxiety sensitivity (AS), a fear of anxiety-related sensations. Given a need for affordable and accessible brief treatments, we and our colleagues have been iteratively developing Brief Enhanced Anxiety Sensitivity Treatment (BEAST), a one-session virtual treatment targeting AS. Older versions of BEAST include psychoeducation, interoceptive exposure (IE), and IE homework. Several studies showed that the previous versions of BEAST reduced AS and, through the reductions in AS, they also reduced anxiety. However, the effect sizes for the decrease in anxiety were modest. Efficacy and personalization may be improved using Ecological Momentary Intervention (EMI). EMI delivers brief interventions remotely in real-time and in natural settings. The goal of the current study is to test the efficacy of adding EMI to BEAST. Participants will be randomly assigned to EMI and control (no EMI) conditions. All participants will receive a virtual 1.5-hour-long intervention group session facilitated by a therapist. The EMI group will receive individualized intervention messages helping them to use new skills for two weeks after the session. After the two-week EMI period, all participants will complete post-treatment measures of AS and anxiety. A month later, they will complete a follow-up assessing AS and anxiety. The efficacy of the EMI component in reducing AS and anxiety will be tested using multilevel modeling. Improving the efficacy of BEAST, while keeping it brief, affordable, and accessible online, is an important step towards making it a treatment that may be used on a large scale.

Eligible Conditions

  • Anxiety

Treatment Effectiveness

Study Objectives

2 Primary · 3 Secondary · Reporting Duration: Baseline, post-treatment including EMI (2 weeks after the session), 1 month follow-up.

Week 2
Daily change - PROMIS Anxiety Short Form 8a Modified (all participants)
Daily change - Short Scale Anxiety Sensitivity Index (all participants)
Week 2
Change multiple times a day - EMI anxiety questions (EMI group)
Baseline
COVID-19 impact battery short-form
Demographic questionnaire
Month 1
Change in PROMIS Anxiety scale - 8a
Change in PROMIS Depression scale - 8a
Change in PROMIS Psychological Stress scale - 8a
Month 1
Change in Anxiety Sensitivity Inventory-3 (ASI-3; Taylor et al., 2007)

Trial Safety

Trial Design

2 Treatment Groups

Control group
1 of 2
EMI group
1 of 2
Active Control
Experimental Treatment

75 Total Participants · 2 Treatment Groups

Primary Treatment: Brief Enhanced Anxiety Sensitivity Treatment (Group BEAST) · No Placebo Group · N/A

EMI group
Behavioral
Experimental Group · 1 Intervention: Brief Enhanced Anxiety Sensitivity Treatment (Group BEAST) · Intervention Types: Behavioral
Control group
Behavioral
ActiveComparator Group · 1 Intervention: Control group Anxiety Sensitivity Treatment · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, post-treatment including emi (2 weeks after the session), 1 month follow-up.
Closest Location: Ohio University · Athens, OH
Photo of oh the ohio state university 1Photo of oh the ohio state university 2Photo of oh the ohio state university 3
2000First Recorded Clinical Trial
1 TrialsResearching Anxiety
31 CompletedClinical Trials

Who is running the clinical trial?

Ohio UniversityLead Sponsor
62 Previous Clinical Trials
36,025 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have elevated anxiety sensitivity symptoms (i.e., ASI-3 scores greater than or equal to 17).

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References